Dr. Guillermo Torre Amione is the President of TecSalud and Vice President of Research, Tecnológico de Monterrey; Chairman of Cardiovascular Research at TecSalud School of Medicine Tecnológico de Monterrey. He is one of the founders of the Transplant Laboratory at Houston Methodist Hospital and was a board member of the DeBakey Heart Center run by Houston Methodist Hospital and the University of St. Thomas. He holds a medical degree from Tecnológico de Monterrey, with a fellowship in Internal Medicine and in Interventional Cardiology, Heart Failure, and Transplantation from Baylor College of Medicine, and a PhD in Immunology from the University of Chicago. Guillermo Torre is a Level 3 member of the Mexican National Research System. His primary research interest has been in pathophysiological basis of heart failure, with particular emphasis in immune regulation. Dr. Torre has published more than 190 scientific articles with more than 12,000 citations (H-index 56), winning the SCOPUS award for the country's most cited author. He has published five books and three patents. During the COVID-19 pandemic, Guillermo has been an active participant in the development of strategies along with private and public sector leaders, including the Foreign Secretary. In TecSalud, he has led research protocols for the diagnosis and treatment of COVID-19, such as Phase 3 clinical trials of the mRNA COVID-19 vaccine manufactured by the CureVac laboratory. He is a member of the Mexican Academy of Medicine, the American College of Cardiology, and the American Heart Association; he is certified as a specialist in Clinical Cardiology by the Mexican Council of Cardiology and certified in Internal Medicine, Cardiology, Heart Failure, and Transplantation by the American Board of Internal Medicine. He is founder of the technology-based health company Nano4Heart and a board member of Cardiol Therapeutics and Sulfagenics, a company dedicated to the development of drugs for the treatment of heart failure.